Organization
Compugen
3 clinical trials
5 abstracts
Clinical trial
A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjects With Advanced Solid Tumors.Status: Active (not recruiting), Estimated PCD: 2024-02-29
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
Real-world use of anti-EGFR therapy in metastatic colorectal cancer.Org: University of Colorado Cancer Center, Aurora, CO, Compugen,
Abstract
The impact of a cancer-specific novel therapy adjustment (NTA) in Medicare value-based care programs: A simulation exercise.Org: US Oncology Network, Dallas, Txinno Bioscience, McKesson, Denver, CO,
Abstract
Precision immuno-oncology (IO) ISH/IF multiplex panel: Spatial detection of cytokines and IO biomarkers.Org: Lanterne Dx, Boulder, CO, Compugen,
Abstract
Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.Org: Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Analysis Group, Inc., Inc.,